Skip to main
URGN
URGN

UroGen Pharma (URGN) Stock Forecast & Price Target

UroGen Pharma (URGN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 17%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

UroGen Pharma Ltd has demonstrated substantial financial growth, with net product revenue increasing by 9% year-over-year to reach $90.4 million for 2024, driven primarily by strong demand for its flagship product, JELMYTO, which alone saw revenue rise to $24.6 million in Q4 2024. The company’s projections indicate a significant upward trajectory, forecasting top-line sales to grow to $114.1 million in 2025 and further to $338.8 million by 2026. Additionally, strong clinical data, particularly the positive 18-month duration of response of 80.6% for UGN-102 in the Phase 3 ENVISION trial, positions UroGen favorably for a potential commercial launch and addresses a sizable market opportunity exceeding $5 billion.

Bears say

UroGen Pharma experienced a significant financial setback, reporting a net loss of $2.96 per share for the full year 2024, which indicates challenges in achieving profitability. The company faced a widening net loss of $37.5 million in Q4, up from $26 million in the previous year, contributing to a total annual net loss of $126.9 million. Key risks include the potential inability to penetrate the market as projected due to increased competition and pricing pressures, along with uncertainties regarding the successful transition to upcoming product candidates and overall clinical trial outcomes.

UroGen Pharma (URGN) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 17% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About UroGen Pharma (URGN) Forecast

Analysts have given UroGen Pharma (URGN) a Buy based on their latest research and market trends.

According to 12 analysts, UroGen Pharma (URGN) has a Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

UroGen Pharma (URGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.